Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients.
Bioimpedance analysis
Fluid retention
Hypoalbuminemia
Responder
Tolvaptan
Volume overload
Journal
International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
13
03
2019
accepted:
21
05
2019
pubmed:
5
6
2019
medline:
28
2
2020
entrez:
5
6
2019
Statut:
ppublish
Résumé
Tolvaptan exerts an aquaretic effect by blocking vasopressin V2 receptor. Although tolvaptan ameliorates body fluid retention even in patients with chronic kidney disease (CKD), predictors of body fluid reduction induced by tolvaptan remain unclear. We, therefore, examined the clinical parameters associated with the effect of tolvaptan on fluid volume in CKD patients. Twelve CKD patients (stage 3-5) with fluid retention were treated with tolvaptan in addition to conventional diuretic treatment. Patients were divided into low and high responders by the median change in total body water (TBW) for 1 week measured by a bioimpedance analysis (BIA) device, and clinical parameters were compared between the groups. The body weight significantly decreased by 2.0 ± 2.3 kg (p = 0.005), but the estimated glomerular filtration rate (eGFR) was not significantly changed (16.9 ± 11.9 vs. 17.4 ± 12.4 mL/min/1.73 m Serum albumin levels predict the body fluid response to tolvaptan in CKD patients. Tolvaptan may be a promising therapeutic option for ameliorating body fluid retention, especially in patients with hypoalbuminemia.
Identifiants
pubmed: 31161520
doi: 10.1007/s11255-019-02180-8
pii: 10.1007/s11255-019-02180-8
doi:
Substances chimiques
Serum Albumin
0
Tolvaptan
21G72T1950
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1623-1629Références
Am J Physiol Endocrinol Metab. 2000 Jul;279(1):E155-60
pubmed: 10893335
Kidney Int. 2005 Jun;67(6):2089-100
pubmed: 15882252
Eur J Heart Fail. 2007 Oct;9(10):1064-9
pubmed: 17719273
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Cardiovasc Res. 2010 Jul 15;87(2):198-210
pubmed: 20200043
Int Urol Nephrol. 2012 Jun;44(3):865-71
pubmed: 21607553
Circ J. 2013;77(2):397-404
pubmed: 23131721
Clin Exp Nephrol. 2013 Dec;17(6):834-8
pubmed: 23483323
Kidney Int. 2014 Jan;85(1):151-7
pubmed: 23884340
Am J Kidney Dis. 2014 Jan;63(1):68-75
pubmed: 23896483
Kidney Int. 2014 Apr;85(4):953-61
pubmed: 24048380
Pediatr Nephrol. 2014 May;29(5):915-7
pubmed: 24240509
Circ J. 2014;78(9):2240-9
pubmed: 24954239
Am J Med Sci. 2014 Nov;348(5):432-9
pubmed: 25247759
Clin J Am Soc Nephrol. 2015 Jan 7;10(1):39-46
pubmed: 25512646
J Gastroenterol. 2015 Oct;50(10):1047-53
pubmed: 25689936
Cardiovasc Ther. 2015 Oct;33(5):275-81
pubmed: 26122275
Hepatol Res. 2017 Jan;47(1):11-22
pubmed: 26990144
Hepatol Res. 2017 Mar;47(3):E14-E21
pubmed: 27059410
PLoS One. 2016 Jul 25;11(7):e0159839
pubmed: 27453993
Intern Med. 2016;55(19):2759-2764
pubmed: 27725533
Intern Med. 2016;55(20):2911-2916
pubmed: 27746425
Clin Exp Nephrol. 2017 Oct;21(5):858-865
pubmed: 28190113
PLoS One. 2017 Mar 31;12(3):e0174649
pubmed: 28362879
Crit Care. 2017 Oct 23;21(1):261
pubmed: 29058634
Intern Med. 2018 Sep 01;57(17):2451-2458
pubmed: 29607963
Nephrology (Carlton). 2018 Sep;23(9):883-886
pubmed: 29665203
Clin Exp Nephrol. 2018 Dec;22(6):1395-1403
pubmed: 29934667
Int Heart J. 2018 Nov 28;59(6):1368-1377
pubmed: 30369583
Nephrology (Carlton). 2019 Sep;24(9):904-911
pubmed: 30578654
Intern Med. 2019 Jun 1;58(11):1587-1591
pubmed: 30713322
Am J Physiol. 1987 May;252(5 Pt 2):R972-8
pubmed: 3578559
J Clin Invest. 1995 Jul;96(1):378-85
pubmed: 7615808
J Pharmacol Exp Ther. 1998 Dec;287(3):860-7
pubmed: 9864265